This study analyzed the role of dopamine D1 and D2 receptors in methylphenidate (MPH) conditioned place preference (CPP) in adolescent male and female rats, in addition to the role of these receptors in the effects of MPH on brain-derived neurotrophic factor (BDNF) in the dorsal striatum and nucleus accumbens. Using a nonbiased CPP procedure, the animals were conditioned from postnatal day (PD) 33 to 37. On conditioning trials, animals were first administered saline or their respective antagonist (0.1 or 0.2 mg/kg SCH-23390; 0.01 or 0.03 mg/kg eticlopride HCl), followed by MPH (5 mg/kg). Approximately 10 min after MPH administration, the rats were placed into the paired context for a 10-min trial. One day after conditioning on PD38, a preference test was administered with dividers removed. One day following the preference test on PD39, brain tissue was removed, and the nucleus accumbens and striatum were analyzed for BDNF. Results revealed that MPH conditioning resulted in an increased preference that was blocked by either dose of SCH-23390, but generally not affected by either dose of eticlopride. Further, the higher dose of SCH-23390 resulted in a conditioned place aversion in males, presumably due to an increased number of dopamine D1 receptors in adolescent males. MPH produced a significant increase of striatal and accumbal BDNF alleviated by SCH-23390 or eticlopride. These results show that MPH results in CPP in adolescent male and female rats and these effects appear to be mediated by the dopamine D1 receptor, but the effects of MPH on BDNF appear to be mediated by both dopamine receptor families.

Keywords:
Methylphenidate, Adolescence, Sex differences, Dopamine receptor, Neurotrophic factor, Drugs of abuse
1.
Karlstad O, Furu K, Skurtveit S, Selmer R: Prescribing of drugs for attention deficit hyperactivity disorder in opioid maintenance treatment patients in Norway. Eur Addict Res 2013;20:59-65.
2.
Prommer E: Methylphenidate established and expanding roles in symptom management. Am J Hosp Palliat Care 2012;29:483-490.
3.
Challman TD, Lipsky JJ: Methylphenidate: its pharmacology and uses. Mayo Clin Proc 2000;75:711-721.
4.
Rubia K, Alegria AA, Cubillo AI, Smith AB, Brammer MJ, Radua J: Effects of stimulants on brain function in attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Biol Psychiatry, Epub ahead of print.
5.
Dupont R, Coleman J, Bucher R, Wilford B: Characteristics and motives of college students who engage in nonmedical use of methylphenidate. Am J Addict 2008;117:167-171.
6.
Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, Utzinger L, Fusillo S: Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008;47:21-31.
7.
Looby A, Earleywine M: Expectation to receive methylphenidate enhances subjective arousal but not cognitive performance. Exp Clin Psychopharmacol 2011;19:433.
8.
Rabiner DL, Anastopoulos AD, Costello EJ, Hoyle RH, McCabe SE, Swartzwelder HS: The misuse and diversion of prescribed ADHD medications by college students. J Attent Disord 2009;13:144-153.
9.
Substance Abuse Mental Health Services Administration: Overview of findings from the 2004 national survey on drug use and health. NSDUH Series H-27, DHHS Publication SMA 05-4061, 2005.
10.
Bardo MT, Bevins RA: Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology 2000;153:31-43.
11.
Tzschentke TM: Review on CPP: measuring reward with the conditioned place preference (CPP) paradigm: update of the last decade. Addict Biol 2007;12:227-462.
12.
Meririnne E, Kankaanpää A, Seppälä T: Rewarding properties of methylphenidate: sensitization by prior exposure to the drug and effects of dopamine D1 and D2 receptor antagonists. J Pharmacol Exp Ther 2001;298:539-550.
13.
Sellings LH, McQuade LE, Clarke PB: Characterization of dopamine-dependent rewarding and locomotor stimulant effects of intravenously administered methylphenidate in rats. Neuroscience 2006;141:1457-1468.
14.
Wooters TE, Walton MT, Bardo MT: Oral methylphenidate establishes a conditioned place preference in rats. Neurosci Lett 2011;48:293-296.
15.
Thanos PK, Bermeo C, Rubinstein M, Suchland KL, Wang GJ, Grandy DK, Volkow ND: Conditioned place preference and locomotor activity in response to methylphenidate, amphetamine and cocaine in mice lacking dopamine D4 receptors. J Psychopharmacol 2010;24:897-904.
16.
de la Pena IC, Ahn HS, Choi JY, Shin CY, Ryu JH, Cheong JH: Methylphenidate self-administration and conditioned place preference in an animal model of attention deficit hyperactivity disorder: the spontaneously hypertensive rat. Behav Pharmacol 2011;22:31-39.
17.
Hempstead BL: Dissecting the diverse actions of pro- and mature neurotrophins. Curr Alzheimer Res 2006;3:19-24.
18.
Reichardt LF: Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci 2006;361:1545-1564.
19.
Autry AE, Monteggia LM: Brain-derived neurotrophic factor and neuropsychiatric disorders. Pharmacol Rev 2012;64:238-258.
20.
Bibel M, Barde YA: Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev 2000;14:2919-2937.
21.
Huang EJ, Reichardt LF: Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 2001;24:677-736.
22.
Bolaños CA, Nestler EJ: Neurotrophic mechanisms in drug addiction. Neuromolecular Med 2004;5:69-83.
23.
Horger BA, Iyasere CA, Berhow MT, Messer CJ, Nestler EJ, Taylor JR: Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. J Neurosci 1999;19:4110-4122.
24.
Brown RW, Hughes BA, Hughes AB, Sheppard AB, Perna MK, Ragsdale WL, Roeding RL, Pond BB: Sex and dose-related differences in methylphenidate adolescent locomotor sensitization and effects on brain-derived neurotrophic factor. J Psychopharmacol 2012;26:1480-1488.
25.
Chase T, Carrey N, Soo E, Wilkinson M: Methylphenidate regulates activity regulated cytoskeletal associated but not brain-derived neurotrophic factor gene expression in the developing rat striatum. Neuroscience 2007;144:969-984.
26.
Fumagalli F, Cattaneo A, Caffino L, Ibba M, Racagni G, Carboni E, Gennarelli M, Riva MA: Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: comparison with methylphenidate. Pharmacol Res 2010;62:523-529.
27.
Cummins ED, Griffin SB, Burgess KC, Peterson DJ, Watson BD, Buendia MA, Stanwood GD, Brown RW: Methylphenidate place conditioning in adolescent rats: an analysis of sex differences and the dopamine transporter. Behav Brain Res 2013;257:215-223.
28.
Andersen SL, Teicher MH: Sex differences in dopamine receptors and their relevance to ADHD. Neurosci Biobehav Rev 2000;24:137-141.
29.
Wargin W, Patrick K, Kilts C, Gualtieri CT, Ellington K, Mueller RA, Kraemer G, Breese GR: Pharmacokinetics of methylphenidate in man, rat and monkey. J Pharmacol Exp Ther 1983;3:382-386.
30.
Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE, Schmeichel B, Hamilton C, Spencer RC: Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 2006;60:1111-1120.
31.
Yates JR, Beckmann JS, Meyer AC, Bardo MT: Concurrent choice for social interaction and amphetamine using conditioned place preference in rats: effects of age and housing condition. Drug Alcohol Depend 2013;129:240-246.
32.
Bardo MT, Gehrke BJ, Shortridge BE, Rauhut AS: Effects of β-funaltrexamine and naloxonazine on single-trial morphine-conditioned place preference and locomotor activity. Pharmacol Biochem Behav 2003;74:617-622.
33.
Botly LC, Burton CL, Rizos Z, Fletcher PJ: Characterization of methylphenidate self-administration and reinstatement in the rat. Psychopharmacology 2008;199:55-66.
34.
Pierre PJ, Vezina P: D1 dopamine receptor blockade prevents the facilitation of amphetamine self-administration induced by prior exposure to the drug. Psychopharmacology 1998;138:159-166.
35.
Shippenberg TS, Heidbreder C: Sensitization to the conditioned rewarding effects of cocaine: pharmacological and temporal characteristics. J Pharmacol Exp Ther 1995;273:808-815.
36.
Andersen SL, Thompson AP, Krenzel E, Teicher MH: Pubertal changes in gonadal hormones do not underlie adolescent dopamine receptor overproduction. Psychoneuroendocrinology 2002;27:683-691.
37.
Andersen SL, Rutstein M, Benzo JM, Hostetter JC, Teicher MH: Sex differences in dopamine receptor overproduction and elimination. Neuroreport 1997;8:1495-1498.
38.
Tang L, Todd RD, Heller A, O'Malley KL: Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. J Pharmacol Exp Ther 1994;268:495-502.
39.
Dreyer JK, Hounsgaard J: Mathematical model of dopamine autoreceptors and uptake inhibitors and their influence on tonic and phasic dopamine signaling. J Neurophysiol 2013;109:171-182.
40.
Wooters TE, Dwoskin LP, Bardo MT: Age and sex differences in the locomotor effect of repeated methylphenidate in rats classified as high and low novelty responders. Psychopharmacology 2006;188:18-27.
41.
Weiss SR, Post RM, Pert A, Woodward R, Murman D: Context-dependent cocaine sensitization: differential effect of haloperidol on development versus expression. Pharmacol Biochem Behav 1989;34:655-661.
42.
Mazurski EJ, Beninger RJ: Effects of selective drugs for dopaminergic D1 and D2 receptors on conditioned locomotion in rats. Psychopharmacology 1991;105:107-112.
43.
Sheppard B, Lehmann J, Cope ZA, Brown RW: Sex differences in nicotine sensitization and conditioned hyperactivity in adolescent rats neonatally treated with quinpirole: role of D2 and D3 receptor subtypes. Behav Neurosci 2009;123:1296-1308.
44.
Bevins RA, Palmatier MI: Nicotine-conditioned locomotor sensitization in rats: assessment of the US preexposure effect. Behav Brain Res 2003;143:65-74.
45.
Brabant C, Tambour S, Quertemont E, Ferrara A, Tirelli E: Do excitatory and inhibitory conditioning processes underlie psychomotor sensitization to amphetamine? An analysis using simple and multiple regressions. Behav Brain Res 2011;221:227-236.
46.
Devilbiss DM, Berridge CW: Low-dose methylphenidate actions on tonic and phasic locus coeruleus discharge. J Pharmacol Exp Ther 2006;319:1327-1335.
47.
Teter CJ, McCabe SE, LaGrange K, Cranford JA, Boyd CJ: Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 2006;26:1501-1510.
48.
Carlezon WA, Konradi C: Understanding the neurobiological consequences of early exposure to psychotropic drugs: linking behavior with molecules. Neuropharmacology 2004;47:47-60.
49.
Bogle KE, Smith BH: Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. Curr Drug Abuse Rev 2009;2:157-176.
50.
Bolaños CA, Nestler EJ: Neurotrophic mechanisms in drug addiction. Neuromolecular Med 2004;5:69-83.
51.
Ghitza UE, Zhai H, Wu P, Airavaara M, Shaham Y, Lu L: Role of BDNF and GDNF in drug reward and relapse: a review. Neurosci Biobehav Rev 2010;35:157-171.
52.
Horger BA, Iyasere CA, Berhow MT, Messer CJ, Nestler EJ, Taylor JR: Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. J Neurosci 1999;19:4110-4122.
53.
Laviola G, Adriani W, Terranova ML, Gerra G: Psychobiological risk factors for vulnerability to psychostimulants in human adolescents and animal models. Neurosci Biobehav Rev 1999;23:993-1010.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.